A worker dies at a Russian plague research institute. Moscow says nothing. The silence is alarming, but two letters to the Guardian argue the real failure is structural, not Russian. Six years after Covid-19, the international system for sharing dangerous pathogens and distributing whatever gets made from them remains unsigned, unfunded, and now deferred to 2027. Darren Mann, former medical director of the UK Cabinet Office Covid-19 PPE taskforce, traces the impasse to its literal origin. In June 1894, two bacteriologists arrived in Hong Kong to investigate bubonic plague. Kitasato Shibasaburō got lab space and bodies. Alexandre Yersin got a straw hut and had to beg the governor for cadavers. Access was allocated by favour, not need. The organism — Yersinia pestis — carries the name of the man who was shut out. The pathogen access and benefit-sharing (PABS) annexe to the WHO pandemic agreement, Mann argues, is the same argument in modern dress. The sticking point is precise and familiar: poorer countries are expected to detect and share dangerous pathogens quickly. In return, they want a binding guarantee — 20% of real-time production of vaccines and treatments, half donated and half sold at cost. Article 13 of the draft agreement provides for more equitable distribution of PPE through a global supply chain and logistics network. Richer countries prefer these commitments to remain voluntary. The agreement cannot open for signature until this is settled. Kent Buse, co-CEO of Global 50/50, sharpens the institutional critique. The International Health Regulations oblige governments to notify the WHO within 24 hours of a public health event, yet provide no verification mechanism, no sanctions, and no independent monitoring. States mark their own homework through annual self-assessments. The IHR amendments in force since September 2024 added an implementation committee that is, by design, consultative only. Member states — Britain included — chose this architecture deliberately, then starved the WHO of assessed funding, leaving it dependent on the goodwill of the governments it is supposed to hold accountable. With the United States withdrawn from the WHO, the UK is now among its largest government funders. Buse argues Britain should raise Russia's non-reporting formally within the WHO rather than leave Washington to make the only public request. He calls for the UK to table proposals for independent verification and a public compliance register when the PABS annexe returns to the World Health Assembly by May 2027. He also notes that only 11 countries have joined the WHO's Universal Health and Preparedness Review — a voluntary peer review — and Britain is not among them. The extraction pattern here is not one government hoarding information from another. It is a system designed so that no government is ever compelled to share anything — pathogens, data, vaccines, or accountability — while the costs of the next pandemic fall on populations with no seat at the table. The 20% production-sharing demand from the Global South is the core tension: wealthy nations want pathogen access without binding reciprocity, poorer nations want reciprocity before they share. Deferral to 2027 means the window between now and the next zoonotic spillover remains ungoverned. Mann's closing line is the sharpest diagnosis in either letter: "All pandemics start with a rumour. The next pandemic is likely to be something we have never seen before, and whoever first holds the samples will not be us. If we cannot agree what they get in return, we should not be surprised when they are slow to hand them over." The incentive structure is clear, and it currently rewards silence.
